Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)

Selpercatinib is a novel, highly selective, small-molecule inhibitor of RET kinase that competes with adenosine triphosphate. In experimental models, this drug has demonstrated nanomolar activity against various RET gene alterations, including an acquired resistance mutation in the gatekeeper gene a...

Full description

Bibliographic Details

Published in:	Опухоли головы и шеи
Main Authors:	E. V. Borodavina, S. I. Kutukova, Т. V. Kekeeva, Р. A. Isaev
Format:	Article
Language:	Russian
Published:	ABV-press 2025-03-01
Subjects:	medullary thyroid cancer radioiodine refractory thyroid cancer progression calcitonin ret mutation targeted therapy selpercatinib
Online Access:	https://ogsh.abvpress.ru/jour/article/view/1045